GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (STU:2L9) » Definitions » Shiller PE Ratio

Blueprint Medicines (STU:2L9) Shiller PE Ratio : (As of Apr. 30, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Blueprint Medicines Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Blueprint Medicines Shiller PE Ratio Historical Data

The historical data trend for Blueprint Medicines's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Shiller PE Ratio Chart

Blueprint Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Blueprint Medicines Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Blueprint Medicines's Shiller PE Ratio

For the Biotechnology subindustry, Blueprint Medicines's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Shiller PE Ratio falls into.


;
;

Blueprint Medicines Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Blueprint Medicines's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Blueprint Medicines's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.754/133.1571*133.1571
=-0.754

Current CPI (Dec. 2024) = 133.1571.

Blueprint Medicines Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.514 99.621 -0.687
201506 -0.722 100.684 -0.955
201509 -0.419 100.392 -0.556
201512 -0.532 99.792 -0.710
201603 -0.512 100.470 -0.679
201606 -0.623 101.688 -0.816
201609 -0.552 101.861 -0.722
201612 -0.711 101.863 -0.929
201703 -0.785 102.862 -1.016
201706 -0.765 103.349 -0.986
201709 -0.805 104.136 -1.029
201712 -1.039 104.011 -1.330
201803 -1.046 105.290 -1.323
201806 -0.531 106.317 -0.665
201809 -1.423 106.507 -1.779
201812 -1.609 105.998 -2.021
201903 -1.752 107.251 -2.175
201906 -1.805 108.070 -2.224
201909 -1.752 108.329 -2.154
201912 -1.215 108.420 -1.492
202003 -1.910 108.902 -2.335
202006 -2.025 108.767 -2.479
202009 9.475 109.815 11.489
202012 -1.258 109.897 -1.524
202103 -1.445 111.754 -1.722
202106 -1.544 114.631 -1.794
202109 -1.700 115.734 -1.956
202112 -4.779 117.630 -5.410
202203 -1.625 121.301 -1.784
202206 -2.535 125.017 -2.700
202209 -2.252 125.227 -2.395
202212 -2.502 125.222 -2.661
202303 -2.008 127.348 -2.100
202306 -2.021 128.729 -2.091
202309 -2.061 129.860 -2.113
202312 -1.669 129.419 -1.717
202403 1.288 131.776 1.301
202406 -0.743 132.554 -0.746
202409 -0.802 133.029 -0.803
202412 -0.754 133.157 -0.754

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Blueprint Medicines  (STU:2L9) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Blueprint Medicines Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Blueprint Medicines Headlines

No Headlines